ODINWELL AB
NNGM:ODIN0.15
SEK
+0.00
(+1.00%)
ISIN
SE0015809967
Return %
Stock
S&P 500
1Y
-52.66
14.20
3Y
-80.14
81.12
5Y
-96.50
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Halmstad Sweden
- IPO Date
- Jun 9, 2021
- Website
- odinwell.com
- Similar Companies
- Business
- Odinwell AB is a Sweden-based medical technology company that develops optical sensor platforms and smart wound care diagnostics for human healthcare and veterinary applications. Founded in 2019 as a spin-off from Redsense Medical AB, the company is headquartered in Halmstad, Sweden. Odinwell utilizes proprietary, patented fiber-optic and fluorescence-based sensing technology to facilitate real-time, non-invasive assessment of covered wounds without requiring dressing removal. The company's core product and technology offerings include the novaQS wound assessment system, an optical measurement tool engineered for veterinary professionals to deliver objective diagnostic data on wound cleanliness and bacterial status; smart dressing sensor platforms, which integrate optical sensor arrays into wound bandages to detect fluid accumulation, blood leakage, pressure variations, and infection biomarkers; and OEM sensor integration and licensing solutions, providing medical dressing manufacturers and clinical partners with embedded diagnostic capabilities for acute, post-surgical, and chronic wound applications including diabetic foot ulcers and venous leg ulcers. In recent corporate developments, Odinwell appointed Marcus Andersson as permanent Chief Executive Officer in September 2024 to accelerate commercialization and business development strategies. The company has prioritized the development, validation, and market rollout of its novaQS veterinary platform. To finance its ongoing product development, regulatory activities, and commercial scaling, Odinwell completed a rights issue of units featuring warrants in the spring of 2025, followed by the exercise of series TO 2 warrants and a fully subscribed directed share issue to board members and executive management in mid-2026.